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The aim of the study was to evaluate adiponectin (AD) serum concentrations in 43 stable CF patients and 27 healthy subjects and to correlate
them with their nutritional status. Body Composition (Bioelectrical Impedance), visceral/subcutaneous adipose tissue (VAT-SAT) in CF patients
(CT-scan at L4), insulin resistance (HOMA-IR) and AD serum concentrations (ELISA) were studied. CF patients and controls had comparable
weight, height, %BF, %FFM, fasting glucose, insulin and insulin resistance. CF patients had significantly lower BMI-SDS. CF males had higher
%FFM and total FFM and lower %BF and total BF than females (pb0.001). Serum AD was higher in CF patients than controls (11.53±5.37 vs.
9.07±4.41 μg/ml) and comparable between females and males. AD was lowest among young malnourished patients (8.06±1.85 μg/ml) and
highest among young patients with normal nutrition (14.56±7.69 μg/ml). Patients with biliary cirrhosis had higher levels than patients with
normal liver (10.52±5.49 vs. 14.04±4.52 μg/ml, pb0.05). AD correlated with %BF, %FFM, FFM (kg) (pb0.05).VATwas significantly increased
in malnourished patients. AD was not affected by VAT. Conclusions: Adiponectin is higher in CF patients than healthy individuals. It is decreased
in malnourished young patients and increased in patients with normal nutrition and in patients with liver disease. This may be attributed to the
reduced BF and to the energy deficit inherent to the disease.
© 2007 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.Keywords: Cystic fibrosis; Adiponectin; Malnutrition; Body composition; Energy deficiency; Liver disease1. Introduction
Adipose tissue (AT) is a major site of energy storage,
important for lipid and glucose homeostasis. [1,2] It also
secretes several biologically active molecules called “adipo-
kines”. [3] Adiponectin is an adipokine, exclusively secreted
by adipocytes. It has recently attracted much attention because
of its anti-inflammatory, anti-diabetic and anti-atherogenic
effects. Low serum adiponectin levels are related to obesity
[4] [especially to the amount of visceral adipose tissue (VAT)],☆ This paper has been accepted for an oral presentation at the 30th European
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doi:10.1016/j.jcf.2007.10.003[5] insulin resistance, [6] type 2 diabetes mellitus [7] and car-
diovascular disease [8] in adults as well as in children. [9]
Furthermore, adiponectin levels are reduced among adult and
paediatric patients with lipodystrophy [10] (especially HIV-
related). [11] On the other hand, elevated serum adiponectin
levels have been reported in conditions with energy deficit such
as anorexia nervosa. [12] Adiponectin tissue mRNA expression
increases with low calorie diets. [13]
Cystic Fibrosis (CF) is an inherited disease often associated
with malnutrition as a result of malabsorption because of
pancreatic insufficiency. Malnutrition leads to decreased body
weight and height. Decreased body weight is a combination
of decreased body fat and fat free mass. [14,15] Cystic fibrosis
patients suffer from malnutrition and depletion of body fat.
On the other hand, they have an energy deficit because of
increased energy requirements. Recent publications had con-
flicting results on the role of adiponectin among stable adult
CF patients. [16,17]ropean Cystic Fibrosis Society.
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adiponectin levels in CF patients (children, adolescents, adults),
to associate them with their nutritional status and body
composition (fat mass, fat free mass, visceral adipose tissue)
and to compare them with those of healthy controls matched for
age and gender.
2. Materials and methods
2.1. Patients
Forty-three cystic fibrosis (CF) patients were included in the
study. They were recruited from the cystic fibrosis outpatient
clinic of a University Hospital. The diagnosis of CF was
confirmed by increased concentration of sweat chloride on two
occasions and genetic testing in all patients. Patients had to be
free from infection for 4 weeks prior to their examination.
Thirty-nine patients had pancreatic insufficiency, thirteen had
CF associated liver disease (CF-LD) and twelve had CF related
diabetes mellitus (CF-DM). Thirty-four patients were colonised
with Pseudomonas aeruginosa and eight had Staphylococcus
aureus.
Twenty-seven healthy subjects, matched for age and gender
were also included in the study. Children and adolescents were
recruited among patients hospitalized in the department for non-
infectious causes. Adult controls were recruited among medical
students and Pediatric residents. They had a BMI between 15th
and 85th percentile for their age and gender. Control subjects
also had to be free from infection during the 4 weeks preceding
the study.
2.2. Study design—methods
Patients were admitted to the hospital after an overnight fast.
They underwent physical examination. Body weight and height
were recorded and body mass index (BMI) was calculated as the
weight (in kg) divided by the square of height (in m2). BMI—zFig. 1. Adiponectin, total and LDL-cholscore (BMI-SDS) was calculated for all subjects using the
on-line software provided by Baylor College of Medicine.
[18] The body composition of the participants was determined
by Bioelectrical Impedance Analysis (B I A) (Body stat, Body
Composition Analyzer, Isle of Man, UK), according to the
instructions of the manufacturer and the National Institute of
Health. [19] Body Fat percent (% BF), BF in kg, Fat Free Mass
percent (FFM %) and FFM in kg, were measured for all sub-
jects. The amounts of abdominal visceral and abdominal sub-
cutaneous adipose tissue were estimated with a single-slice CT
scan at the level of the umbilicus or at the level of the L3–L4
vertebrae (Spiral Single Slice scanner: PQ 5000, Picker. Soft-
ware: Analyze, version 5.0, Mayo Clinic). [20] Blood samples
were drawn from CF patients and healthy controls. The fol-
lowing tests were performed in all subjects: complete blood
count, biochemistry (glucose, albumin, total cholesterol,
triglycerides, HDL- and LDL-cholesterol), C-reactive protein,
fasting insulin, HbA1c %. Serum insulin levels were measured
applying a solid-phase, two-site chemiluminescent immuno-
metric assay (Immulite 2000; DPC, USA) with a 2 μIU/mL
sensitivity. Fasting whole blood samples were centrifuged
immediately after collection and serum samples were stored
at −24 °C, for the measurement of adiponectin. For this purpose
a commercial quantitative sandwich enzyme immunoassay tech-
nique was used according to the manufacturer's guidelines
(Quantikine Human Adiponectin, R & D Systems, USA).
The minimum detectable level of the assay was 0.25 ng/ml.
For the estimation of insulin resistance (IR), indices derived
from fasting glucose and fasting insulin values were used: Ho-
meostasisModelAssessment for InsulinResistance (HOMA: IR)=
[(fasting glucose [mmol/L)×(fasting insulin [μU/mL)])/22.5
[21] and Fasting Glucose to Fasting Insulin Ratio (FGIR). [22]
The patients were divided according to their age into
individuals younger than 17 years (children and adolescents)
and patients older than 17 years (adults). They were also
divided according to their nutritional status. Patients having
a BMI below the 15th percentile for their age and genderesterol in CF patients and controls.
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between the 15th and 95th percentiles were regarded as
having normal nutritional status. Patients having a BMI
above the 95th percentile were excluded from the study as
“obese”.
Seventeen malnourished CF patients (mean age±SD: 20.52±
7.41 years) were compared with 26 normally nourished CF
patients (mean age±SD: 19.71±9.36 years) and with 27 healthy
subjects (BMI between the 15th and 85th percentiles) matched
for age and gender.
2.3. Statistical analysis
Descriptive statistics were computed for all variables
of interest. Kolmogorov-Smirnov test was used to test the
normality of distribution. Data are shown as means±SD
for normally distributed variables. For variables that were
normally distributed, differences between subgroups were
calculated using a Student's t-test for independent samples.
For variables not normally distributed, Mann–Whitney U test
for independent samples was used. Pearson correlation analysis
was used to analyze bivariate relationships and to test for
association between adiponectin concentrations and body
composition and nutrition indices (BMI, BMI-SDS, % BF, BF
in Kg, % FFM, FFM in Kg, VAT and % VAT), metabolic
parameters (fasting insulin, glucose, and serum albumin and
lipid levels) as well as insulin resistance indices (HOMA-IR,
FGIR). Linear regression was used to test for the associationTable 1
Anthropometric and metabolic characteristics and adiponectin levels in CF patients
BMIb15th B
Number (N) 17 2
Age (yrs) 20.52±7.41 1
Weight (kg) 47.51±10.77 5
Height (cm) 163±12 1
BMI (Kg/m2) 17.51±1.92 2
BMI-SDS −1.81±0.79 0
% BF 14.17±5.02 2
BF (kg) 6.79±2.28 1
% FFM 85.28±5.02 7
FFM (kg) 40.72±10.52 3
FEV1 (% pred) 55.50±17.86 7
VAT/Total adipose tissue 52% 3
Adiponectin (μg/ml) 9.91±3.55 1
(All CF patients) 11.53±5.37
Cholesterol (mg/dl) 98.92±26.07 1
Triglycerides (mg/dl) 63.69±19.79 8
HDL-Cholesterol (mg/dl) 38.70±11.09 5
LDL-Cholesterol (mg/dl) 54.40±14.26 6
Albumin (mg/dl) 4.01±0.54 4
Fasting Glucose (mg/dl) 93±13 9
Fasting Insulin (μIU/ml) 9±8 8
FGIR 21.59±17.28 1
HOMA-IR 2.13±2.10 2
CF: Cystic Fibrosis, HDL-Cholesterol: High Density Lipoprotein-cholesterol, LDL
Insulin Ratio, HOMA-IR: Homeostasis Model assessment for Insulin Resistance, BM
% BF: percent Body Fat, % FFM: percent fat free mass.
Data are expressed as: Mean±Standard Deviation.between adiponectin levels and liver disease. Chi-square test
was used for categorical variables. Statistical analysis was
performed using the SPSS version 12.0 software (Statistical
Package for Social Science Inc, Chicago, Ill. USA). Statistical
significance was set at the pb0.05 level.
2.4. Ethical considerations
The study was approved by the Aristotle University of
Thessaloniki Medical School Ethics Committee and fulfilled the
criteria of the Helsinki Declaration. Written informed consent
was obtained from the parents of the children and adolescents.
3. Results
Cystic fibrosis patients had significantly higher adipo-
nectin levels (11.53±5.37 μg/ml) than control subjects (9.07±
4.41 μg/ml) (pb0.05). They also had significantly lower BMI-
SDS, total and LDL-cholesterol levels (Fig. 1). In comparison
to CF patients with normal nutrition, malnourished CF patients
had lower adiponectin, total and LDL-cholesterol (Table 1). In
comparison to healthy controls, CF patients with normal nutri-
tion had higher adiponectin (12.58±6.12 vs. 9.07±4.41 μg/ml,
pb0.05), significantly higher %BF and BF in kg, significantly
lower total and LDL-cholesterol levels. In comparison to CF
patients with malnutrition, CF patients with normal nutrition had
lower percentage of visceral adipose tissue and significantly
higher FEV1% predicted (Table 1). There was no differencewith and without malnutrition and control subjects
MI 15th–95th Controls p
6 27 –
9.78±9.29 19.88±9.42 ns
1.83±14.77 56.58±18.81 ns
56±16 164±20 ns
0.62±2.36 20.04±3.11 0.001
.079±0.56 −0.05±0.60 0.000
4.21±5.89 18.84±5.89 0.000
2.22±3.71 10.63±4.95 0.000
5.58±5.89 81.15±5.89 0.000
9.68±12.87 45.94±16.29 ns
6.60±26.41 – b0.05
1% – 0.003
2.58±6.12 9.07±4.41 b0.05
9.07±4.41 b0.05
26.78±27.04 154.18±29.05 0.000
3.65±51.97 66.54±31.04 ns
8.95±88.52 57.60±15.31 ns
7.52±21.24 88.20±23.15 0.000
.22±0.43 – ns
4±28 88±10 ns
±7 6±3 ns
8.26±14.52 17.62±11.78 ns
.38±3.80 1.49±0.86 ns
-cholesterol: Low Density Lipoprotein-cholesterol. FGIR: Fasting Glucose to
I: Body Mass Index, BMI-SDS: Body Mass Index-Standard Deviation Score,
Table 2
Demographic and anthropometric characteristics of CF and control subjects
CF with malnutrition CF without malnutrition Control group
b17 years (Α) N17 years (Β) b17 years (C) N17 years (D) b17 years (Ε) N17 years (F)
Number (N) 5 12 11 15 13 14
Age (yrs) 12.73±3.89 23.76±5.95 11.45±3.48 25.88±7.10 11.67±3.2 27.5±6.19
Sex (male/female) 3/2 7/5 4/6 8/8 7/6 6/8
Weight (kg) 37.5±11.5 51.66±7.55 # $ 39.51±13.2 60.8±7.6 #, ⁎ 42.7±15.9 69.47±10.04⁎,$
Height (cm) 152±17 168±7 # 143±15 $ 166±8 $,⁎ 151±20 177±8 ⁎, #
BMI (Kg/m2) 15.84±1.72 $ 18.21±1.57 #, ⁎ 18.6±2.16 $ 21.94±1.45 # 17.8±2.5 22.05±2.15⁎
BMI-SDS −1.56±0.76 ⁎,$ −1.09±0.81 #, $ 0.38±0.76 $ −0.11±0.40 # −0.039±0.55⁎ −0.065±0.67 $
% BF 14.88±4.3 $ 14.61±5.47 ⁎ 27.9±4.06 #, $ 21.48±5.25 ⁎ 17.7±4.1 # 19.82±7
BF (kg) 4.85±3.56 7.26±2.11 ⁎ 11.2±4.46 12.93±3.05 ⁎ 7.3±3.4 13.48±4.29
% FFM 85±4.3 85.38±5.47 ⁎ 72±4.65 78.5±5.25 ⁎ 82.3±4.10 80.17±7.09
FFM (kg) 31.9±9.67 44.4±8.7 28.3±9.31 47.9±7.96 ⁎ 34.2±13 55.99±10.94 ⁎
VAT/Total Fat 49% ⁎ 53% # 34% ⁎ 29% # – –
FEV1 (% pred) 65.3±18 61±23 85.8±4 74±20 – –
CF: cystic fibrosis, BMI: Body Mass Index, BMI-SDS: Body Mass Index-Standard Deviation Score, % BF: percent Body Fat, % FFM: percent Fat Free Mass, VAT:
Visceral Adipose Tissue, FEV1%: Forced Expiratory Volume in 1 s, % predicted.
Data are expressed as: Mean±Standard Deviation.
Statistically significant differences $, &: pb0.05 §, ⁎: pb0.001 #, ‡: pb0.000.
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position parameters [CF males had higher %FFM and total
FFM and lower %BF and total BF than females (pb0.001)].
The demographic and anthropometric characteristics of
CF patients as well as those of healthy controls are shown in
Table 2. By definition, young and adult malnourished CF
patients (groups A and B) had significantly lower BMI and
BMI-SDS, when compared to normally nourished CF patients
(groups C and D) and to healthy controls (groups E and F). They
also had significantly lower % BF, absolute BF in kg, % FFM,
but comparable absolute FFM in kg. Furthermore, adult CF
patients (Groups B and D) were significantly shorter than
healthy controls (Group F). Young CF patients with normal
nutrition (Group C) had significantly higher absolute body
fat in kg and percent body fat than healthy control subjects
(Group E). Both young and adult malnourished CF patients had
significantly higher percentage of visceral adipose tissue inTable 3
Biochemical investigations of CF and control subjects
CF with malnutrition CF
b17 years (Α) N17 years (Β) b17
Number (N) 5 12 11
Adiponectin (μg/ml) 8.06±1.85 $ 10.68±3.86 14.5
Cholesterol (mg/dl) 88±37 & 102±23 $ 129
Triglycerides 48±26 68±16 69±
HDL-Cholesterol (mg/dl) 43±16⁎ 37±10 42±
LDL-Cholesterol (mg/dl) 50±10 $ 55±15 71±
Albumin (mg/dl) 4.12±0.69 4.09±0.51 4.38
Fasting Glucose (mg/dl) 90±9 94±15 88±
Fasting Insulin (μIU/ml) 12.7±9.3 7.51±7.82 6.6
FGIR 11.58±8.10 26.16±18 18±
HOMA-IR 2.77±1.87 1.84±2.2 1.5
CF: Cystic Fibrosis, HDL-Cholesterol: High Density Lipoprotein-cholesterol, LDL
Insulin Ratio, HOMA-IR: Homeostasis Model assessment for Insulin Resistance.
Data are shown as: mean±SD for normally distributed variables.
⁎, #, ‡, &, $: statistically significant differences (pb0.05).comparison to CF patients without malnutrition. Finally, mal-
nourished CF patients had lower (but not significantly) FEV1%
than CF patients with normal nutrition.
Biochemical data (adiponectin, serum lipids, albumin),
fasting glucose and insulin concentrations and IR indices
derived from these values (FGIR, HOMA-IR) in CF patients
according to their nutritional status and in healthy controls are
demonstrated in Table 3. Malnourished CF patients had sig-
nificantly lower serum lipid levels when compared to patients
with normal nutrition and healthy controls. All groups had
comparable glucose, insulin and insulin resistance levels. With
regard to adiponectin (Table 3, Fig. 2), young malnourished
CF patients had significantly lower levels (Group A: 8.06±
1.85 μg/ml) when compared to young CF patients with normal
nutrition (Group C: 14.56±7.69 μg/ml)] (pb0.05). Young mal-
nourished CF patients had lower levels (but not significantly)
than those of healthy controls (Group E: 9.84±4.45 μg/ml).without malnutrition Control group
years (C) N17 years (D) b17 years (E) N17 years (F)
15 13 14
6±7.69 $ 11.13±4.40 9.84±4.45 8.35±4.42
±35 $ 124±20 $ 154±29 & 208±42 #
39 $ 94±59 $ 66±31 60±27
12 $ 38±6 $, # 57±15 ⁎ 49±7 #
25 64±18, # 88±23$, ⁎ 101±34 #
±0.37 4.11±0.04 6.05±0.68 6.38±0.46
12 97±36 # 84±9 92.7±9.5 #
±3.9 10.06±9.73 8.26±4.36 5.39±2.18
10 18.4±17 13.15±8.44 21.76±13.18
±1.1 3.01±4.89 1.77±1.09 1.22±0.49
-cholesterol: Low Density Lipoprotein-cholesterol. FGIR: Fasting Glucose to
Fig. 2. Adiponectin levels in various subgroups according to age and nutritional
status.
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not significantly) than those of healthy individuals. Among
adult CF patients, the presence of malnutrition did not affect
adiponectin levels (10.68±3.86 vs. 11.13±4.40 μg/ml). They
were higher but not significantly than those of healthy controls
(8.35±4.42 μg/ml).
One significant parameter that seemed to influence adipo-
nectin levels was the presence of liver disease. Patients with
nodular biliary cirrhosis had significantly higher levels than
patients with normal liver (10.52±5.49 μg/ml vs. 14.04±
4.52 μg/ml, Mann–Whitney U test, pb0.01) (Fig. 3). More
specifically, in the patient group with liver disease the presence
of malnutrition did not significantly affect adiponectin levels
(13.026±3.98 μg/ml vs. 14.9±6.14 μg/ml, respectively,Fig. 3. Adiponectin levels according to the presence of liver disease.
Fig. 4. Pearson correlation of adiponectin a) with BMI-SDS among CF patients
b) with fat free mass (in Kg) in all subjects.pN0.05). On the other hand, in the patient group without liver
disease the presence of malnutrition significantly affected adipo-
nectin levels (8.22±1.82 μg/ml vs. 11.7±6.01 μg/ml, respec-
tively, pb0.05). Stepwise linear regression analysis with
adiponectin as a dependent variable and liver disease, BMI-Table 4
Pearson correlation between adiponectin levels and anthropometric
characteristics in all subjects (n=70)
R P
Weight −0.259 0.030
Height −0.323 0.006
%BF 0.292 0.015
%FFM −0.292 0.015
FFM (kg) −0.306 0.010
%BF: percent Body Fat, % FFM: percent fat free mass, FFM: Fat FreeMass in kg.
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that the only predictors in the model were liver disease and
BMI-percentile.
Furthermore, adiponectin levels appeared to be associated
with BMI-SDS (Pearson correlation coefficient, r=0.333,
0b0.05) (Fig. 4a). There was no correlation of adiponectin
with demographic and anthropometric parameters, with
biochemical and insulin resistance indices regardless of gender
and age.When patients and control subjects were examined as a
group, adiponectin levels correlated significantly to weight,
height, %BF, %FFM and FFM in kg (Table 4, Fig. 4b).
4. Discussion
This is the first time that adiponectin levels were related to
the nutritional status in CF patients. Young malnourished CF
patients had the lowest levels of adiponectin. This may be
related to their reduced absolute amount and percentage of body
fat. This finding is in accordance with studies which have
shown low adiponectin levels in patients with congenital or
acquired lipodystrophy. Reduced adiponectin levels were found
in an experimental animal model of lipoatrophic subjects [24]
and in patients with generalised lipodystrophy, in proportion to
the extent of fat loss. On the contrary, adiponectin was similar in
patients with partial lipodystrophy and normal healthy subjects.
[10] Reduced adiponectin levels have been demonstrated in
HIV-positive patients with Highly Active Antiretroviral Treat-
ment (HAART)-induced lipodystrophy. [11] Low adiponectin
in malnourished CF patients may be attributed to the reduced
amount of total body fat and the increased percentage of VAT.
The second finding was that adiponectin levels were
increased in young CF patients having normal nutrition as
compared to malnourished young CF patients as well as healthy
controls. Moriconi et al., demonstrated elevated adiponectin
among adult CF patients. They showed increased central fat
accumulation in adult CF patients as compared to healthy
controls matched for BMI, age, and sex. The serum concentra-
tions of adiponectin were higher in CF patients than in controls,
even after adjustment for known confounders. This was attrib-
uted to the negative energy balance that often characterizes
CF. [16] A recent study by Hammana et al., compared 90 CF
patients with 15 healthy controls. Contrary to the first study,
they did not find any alterations in adiponectin levels despite
insulin resistance, glucose intolerance and subclinical chronic
inflammation. Women had higher adiponectin concentrations.
Adiponectin correlated significantly with total and HDL-
cholesterol. They concluded that CF appears to be one of the
rare conditions in which discordance between adiponectin and
insulin resistance or inflammation is evident. [17]
As far as we know this is the first study of adiponectin levels
in relation to the nutritional status of CF patients. Furthermore,
it is the first study of adiponectin among CF children and
adolescents. In the study by Hammana et al., adiponectin was
viewed as a marker of insulin resistance and inflammation,
therefore its relationship to fibrinogen and CRP was examined.
Moriconi et al., examined adiponectin as a marker of energy
deficiency. Qi et al., showed that adiponectin acted on the brainto reduce body weight. Both systematic administration and
intra-ventricular injection of adiponectin resulted in increased
thermogenesis, reduction of blood glucose and lipids. Body
weight was reduced through an increase in energy expenditure.
[25] Other animal studies however, suggested a negative effect
on energy expenditure. [26] Studies in humans showed a
negative correlation between resting metabolic rate and adipo-
nectin in Caucasians. [27] Among Pima Indians, a negative
correlation was found between adiponectin and energy expen-
diture, probably related to body fat distribution. [28] Adipo-
nectin levels have been related to energy deficiency conditions.
Adiponectin mRNA in subcutaneous fat (but not in plasma) rose
quickly during significant, short-term energy intake restriction
(Very Low Calorie Diet, VLCD, 600–800 Kcal/day). [13]
Others failed to demonstrate that VLCD-induced weight reduc-
tion and metabolic changes were accompanied by elevation of
adiponectin. [29] The same applied to patients who followed
an intensive exercise program. [30,31] Anorexia nervosa
(AN) patients are a group experiencing severe negative energy
balance. They have increased adiponectin [12,33–37] while
resistin and leptin are decreased. [32] They also have increased
insulin sensitivity possibly related to increased adiponectin
levels. [38] Only one study showed that patients with AN and
bulimia had lower adiponectin than controls, which returned to
normal after body weight restoration. [39] It is widely accepted
that CF patients have an increased risk of malnutrition because
of the chronic energy deficiency and the negative energy
balance. [40] This may explain our findings. Yet, contrary to
Moriconi et al., we did not find any association between adipo-
nectin and serum concentrations of albumin, a marker of protein
malnutrition. However, an association between adiponectin and
serum lipids was demonstrated.
The third finding was that malnourished CF patients
had significantly higher percentage of VAT in comparison
to patients without malnutrition, despite the significantly
decreased body fat (absolute amount and percentage). Both
groups had comparable fat free mass, which was lower to that
of healthy controls. Moriconi et al., also found increased central
fat in CF patients in comparison to healthy controls, attributed
to CF-related factors (chronic inflammation, corticosteroids,
physical inactivity, anabolic hormones or relative growth hor-
mone deficiency). [16] In the present study, VATwas measured
with CT-scan only in CF patients; therefore comparisons were
only possible between patients with and without malnutrition.
None of our patients received corticosteroids. Finally, although
central fat is associated with insulin resistance, HOMA-IR
and FGIR did not differ between patients with and without
malnutrition.
The fourth observation of the study was that adiponectin
levels were increased among CF patients with biliary cirrhosis.
They were normal among patients without liver disease. The
presence of malnutrition did not affect adiponectin concentra-
tions in this patient group. Elevated adiponectin has been
described among patients with cirrhosis. Tacke et al., demon-
strated elevated adiponectin in chronic liver disease, attributed
to liver damage and inflammation. High adiponectin levels after
bile duct ligation in mice and in human bile from patients
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adiponectin clearance and that adiponectin could serve as
a novel marker indicating cholestasis in liver cirrhosis. [41]
Tietge et al., also found that adiponectin levels were signifi-
cantly elevated in cirrhosis. They did not correlate with pa-
rameters of body composition or metabolism. They correlated
exclusively with reduced liver function and altered hepatic
hemodynamics. They concluded that the liver was a major
source of adiponectin extraction. [42] Our findings are in
accordance with these data and were taken into consideration in
the interpretation of the results.
Limitations of our study include the small number of
subjects, its cross-sectional design as well as the fact that CF
patients had a varying degree of disease severity, making it a
heterogeneous population.
In conclusion, our study revealed elevated adiponectin levels
among young CF patients with normal nutrition which may be
attributed to the energy deficit inherent to the disease and low
adiponectin levels among malnourished CF patients probably
attributed to lipodystrophy-like body fat reduction. It also
revealed that CF patients with biliary cirrhosis had increased
adiponectin levels. Patients with malnutrition tended to have
a more central fat distribution with increased visceral adipose
tissue. More studies are warranted to further elucidate the role
of adiponectin as a marker of liver disease and also of energy
deficiency and imminent malnutrition among growing CF
patients.
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